Sickle cell disease Flashcards

1
Q

inheritance pattern of sickle cell disease

A

Autosomal recessive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

SCD diagnostic methods

A
  1. sickling test ( does not differentiate between carrier and disease)
  2. hemoglobin electrophoresis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

when does HbS polymerization occur

A

upon deoxygenation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what is the effects of hemolysis

A

eads to chronic anemia and nitric oxide depletion/releasing heme

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Sickle RBCs lead to (3 points)

A
  1. Vaso-occlusion
  2. Promote inflammation
  3. Injure endothelium (vasculopathy)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

severe SCD is associated with (_) Wbc

A

higher

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Neutrophil interacts with Sickle RBCs promoting

A

vaso- occlusion.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Neutrophils are activated with increased adhesive properties to endothelium

A

(P- and E-selectins)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Activated platelets bind to

A

neutrophils to form aggregates (P- selectin dependent)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what promote adhesion of Sickle
RBCs to endothelium.

A

Platelets are activated in SCD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what are Sickle cell acute crises triggers

A

 Hypoxia
 Altitude
 Dehydration ( severe exercise) — always keep hydrated
 Infection
 Stress ( procedure/surgery)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what is a cornerstone for management of SCD complications

A

Transfusion therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Acute Painful crises
( General Management )

A

 IV Hydration
 Pain Control ( NSAIDS/OPIODS)
 Oxygen if indicated
 Transfusion if indicated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Oral penicillin reduces incidence of

A

pneumococcal sepsis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Discontinuation of penicillin prophylaxis can be considered at age

A

5 yrs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what reduces frequency of painful episodes, ACS, transfusions, hospitalizations

A

hydroxyurea

17
Q

SCD patients develop splenic dysfunction as early as

A

3 months

18
Q

Increased risk for septicemia and meningitis ( 3organisms)

A

 Streptococcus Pneumoniae
 H. Influenzae type B
 Neisseria meningitidis

19
Q

Osteomyelitis (2organisms)

A

 Salmonella species
 Staphylococcus aureus

20
Q

Preventive Measures

A
  1. Newborn screening/parental education
  2. Prophylactic penicillin by 2 months of age
  3. Immunizations
21
Q

An acutely enlarging spleen and hemoglobin level dropping more than 20 g/L below the patient’s baseline value

A

Splenic Sequestration

22
Q

Splenic Sequestration Clinical manifestations:

A

 Weakness, pallor, tachycardia, irritability
 Left abdominal pain, splenomegaly
 Can progress to shock and death

23
Q

Induces HbF expression in RBCs
Reduction in neutrophil count
Suppresses neutrophil activation
Reductions of adhesion of sickle RBCs to endothelium
Increases nitric oxide

A

Management of SCD Hydroxyurea

24
Q

The only curative therapy for SCD.

A

Stem Cell Transplantation

25
Q

what is the most common variant of sickle cell disease

A

Homozygous sickle cell anemia (HbSS)

26
Q

what is Typically the earliest manifestation of sickle cell disease

A

Dactylitis

27
Q

Most common acute complication of sickle cell disease

A

Vasoocclusive crises (sickle cell pain crisis)

28
Q

when do we see Howell-Jolly bodies

A

occur with splenic dysfunction

29
Q

what indicates the presence of hemolysis

A

Reticulocytosis

30
Q

Possible adverse effects of hu

A

Darkening of skin and nailbeds
Myelosuppression
An atypical form of macrocytosis (nonmegaloblastic anemia)